Enantia
About Enantia
Contract research and development services are delivered by Enantia within the pharmaceutical industry, with emphasis on medicinal chemistry and solid-state forms. Expertise encompasses small molecule design, asymmetric synthesis, cocrystal development, and analytical methods. Challenges in chemical synthesis are addressed, including route optimization, impurity analysis, and solid form characterization. Performance testing and handling of potent compounds are included in the scope of operations.
-
Sectors
Chemicals & Materials
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enantia
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Enantia
Detailed funding history for Enantia
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Enantia
Enantia has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Inveready.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Inveready is recognized as a leading Spanish financial services firm.
|
Locked | Locked | Locked |
Investor details for Enantia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enantia
Investment portfolio details for Enantia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enantia
Detailed financials for Enantia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enantia Comparisons
Peer comparison for Enantia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enantia
Detailed competitors of Enantia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enantia
Complete news archive for Enantia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enantia
Contract research and development services are delivered by Enantia within the pharmaceutical industry, with emphasis on medicinal chemistry and solid-state forms. Expertise encompasses small molecule design, asymmetric synthesis, cocrystal development, and analytical methods. Challenges in chemical synthesis are addressed, including route optimization, impurity analysis, and solid form characterization. Performance testing and handling of potent compounds are included in the scope of operations.
Enantia has 1 investor. Key investors include Inveready.